Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322421 | 0.93 | PKM (0.55) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL24322428 | 0.93 | PKM (0.61) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL13655375 | 0.79 | LMNA (0.84) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL24322783 | 0.74 | PKM (0.53) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL24322388 | 0.74 | RAB9A (0.51) | KDM4ERAB9AALDH1A1KMT2ANPC1 | |
| SCHEMBL29497614 | 0.70 | GAA (1.00) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL24322620 | 0.70 | SMN1; SMN2 (0.44) | GAARAB9APOLBEPHX1ALDH1A1 | |
| SCHEMBL8587098 | 0.70 | LMNA (0.68) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL17817601 | 0.70 | LMNA (0.68) | PKMLMNAKDM4EGAARAB9A | |
| SCHEMBL2347336 | 0.70 | GAA (0.70) | LMNAKDM4EGAARAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | PKM 4535/4885LMNA 1889/4885KDM4E 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.